公开(公告)号：US08030318B2

公开(公告)日：2011-10-04

申请号：US11909118

申请日：2006-03-27

Applicant: Kenneth Alan Simmen ,  Dominique Louis Nestor Ghislain Surleraux ,  Tse-I Lin ,  Oliver Lenz ,  Pierre Jean-Marie Bernard Raboisson ,  Sarvajit Chakravarty ,  Barry Patrick Hart

Inventor： Kenneth Alan Simmen ,  Dominique Louis Nestor Ghislain Surleraux ,  Tse-I Lin ,  Oliver Lenz ,  Pierre Jean-Marie Bernard Raboisson ,  Sarvajit Chakravarty ,  Barry Patrick Hart

IPC: A61K31/519 ,  C07D471/04

CPC classification number: C07D471/04 ,  A61K31/495

Abstract: Substituted fused bicyclic pyrimidine compounds having an amide-substituted pyridylamine group at C-4 of the pyrimidine ring are useful in the treatment of conditions associated with HCV.

Abstract translation: 在嘧啶环的C-4处具有酰胺取代的吡啶基胺基的取代的稠合双环嘧啶化合物可用于治疗与HCV相关的病症。

公开(公告)号：US20110171174A1

公开(公告)日：2011-07-14

申请号：US13119466

申请日：2009-09-18

Applicant: Tse-I Lin ,  Oliver Lenz

Inventor： Tse-I Lin ,  Oliver Lenz

IPC: A61K38/21 ,  A61K31/7068 ,  A61P31/14

CPC classification number: A61K31/513 ,  A61K31/18 ,  A61K31/4709 ,  A61K31/7056 ,  A61K2300/00

Abstract: The present invention relates to a synergistic combination of the compound of formula I: or a pharmaceutically acceptable salt thereof, and the compound of formula II: or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明涉及式I化合物或其药学上可接受的盐与式II化合物或其药学上可接受的盐的协同组合。

公开(公告)号：US07960387B2

公开(公告)日：2011-06-14

申请号：US10545453

申请日：2004-01-29

Applicant: Tobias Wunberg ,  Judith Baumeister ,  Ulrich Betz ,  Mario Jeske ,  Gerald Kleymann ,  Thomas Lampe ,  Susanne Nikolic ,  Jürgen Reefschläger ,  Rudolf Schohe-Loop ,  Frank Süβmeier ,  Holger Zimmermann ,  Rolf Grosser ,  Kerstin Henninger ,  Guy Hewlett ,  Jörg Keldenich ,  Thomas Krämer ,  Peter Nell ,  Tse-I Lin

Inventor： Tobias Wunberg ,  Judith Baumeister ,  Ulrich Betz ,  Mario Jeske ,  Gerald Kleymann ,  Thomas Lampe ,  Susanne Nikolic ,  Jürgen Reefschläger ,  Rudolf Schohe-Loop ,  Frank Süβmeier ,  Holger Zimmermann ,  Rolf Grosser ,  Kerstin Henninger ,  Guy Hewlett ,  Jörg Keldenich ,  Thomas Krämer ,  Peter Nell ,  Tse-I Lin

IPC: A61K31/497 ,  A61P31/12 ,  C07D401/04 ,  C07D239/84

CPC classification number: C07D239/84

Abstract: The invention relates to dihydroquinazolines and methods for the production thereof, the use thereof in the treatment and/or prophylaxis of diseases, in addition to the use thereof in the production of medicaments in the treatment and/or prophylaxis of diseases, especially for use as anti-viral agents, especially against cytomegalo viruses.

Abstract translation: 本发明涉及二氢喹唑啉及其制备方法，其用于治疗和/或预防疾病的用途，除了在制备药物中用于治疗和/或预防疾病，特别是用作 抗病毒剂，特别是针对巨细胞病毒。

公开(公告)号：US07709491B2

公开(公告)日：2010-05-04

申请号：US10534138

申请日：2003-10-25

Applicant: Tobias Wunberg ,  Judith Baumeister ,  Mario Jeske ,  Susanne Nikolic ,  Frank Süβmeier ,  Holger Zimmermann ,  Rolf Grosser ,  Kerstin Henninger ,  Guy Hewlett ,  Jörg Keldenich ,  Dieter Lang ,  Tse-I Lin

Inventor： Tobias Wunberg ,  Judith Baumeister ,  Mario Jeske ,  Susanne Nikolic ,  Frank Süβmeier ,  Holger Zimmermann ,  Rolf Grosser ,  Kerstin Henninger ,  Guy Hewlett ,  Jörg Keldenich ,  Dieter Lang ,  Tse-I Lin

IPC: A61K31/517 ,  C07D239/74 ,  C07D405/10

CPC classification number: C07D239/74

Abstract: The invention relates to substituted quinazolines and to methods for the production thereof, in addition to the use thereof in the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, especially against cytomegaloviruses.

Abstract translation: 本发明涉及取代喹唑啉及其生产方法，除了其用于生产用于治疗和/或预防疾病的药物，特别是用作抗病毒剂，特别是抗巨细胞病毒的药物。

公开(公告)号：US20060235032A1

公开(公告)日：2006-10-19

申请号：US10534138

申请日：2003-10-25

Applicant: Tobias Wunberg ,  Judith Baumeister ,  Mario Jeske ,  Susanne Nikolic ,  Frank Submeier ,  Holger Zimmermann ,  Rolf Grosser ,  Kerstin Henninger ,  Guy Hewlett ,  Jorg Keldenich ,  Dieter Lang ,  Tse-I Lin

Inventor： Tobias Wunberg ,  Judith Baumeister ,  Mario Jeske ,  Susanne Nikolic ,  Frank Submeier ,  Holger Zimmermann ,  Rolf Grosser ,  Kerstin Henninger ,  Guy Hewlett ,  Jorg Keldenich ,  Dieter Lang ,  Tse-I Lin

IPC: A61K31/517 ,  C07D239/72 ,  C07D405/02

CPC classification number: C07D239/74

Abstract: The invention relates to substituted quinazolines and to methods for the production thereof, in addition to the use thereof in the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, especially against cytomegaloviruses.

Abstract translation: 本发明涉及取代喹唑啉及其生产方法，除了其用于生产用于治疗和/或预防疾病的药物，特别是用作抗病毒剂，特别是抗巨细胞病毒的药物中。

公开(公告)号：US09987277B2

公开(公告)日：2018-06-05

申请号：US12443190

申请日：2007-10-04

Applicant: Pierre Jean-Marie Bernard Raboisson ,  Oliver Lenz ,  Tse-I Lin ,  Kenneth Simmen

Inventor： Pierre Jean-Marie Bernard Raboisson ,  Oliver Lenz ,  Tse-I Lin ,  Kenneth Simmen

IPC: A61K31/21 ,  A61K31/506 ,  A61K31/535

CPC classification number: A61K31/506 ,  A61K31/535 ,  A61K2300/00

Abstract: The present invention relates to the use of carboxamide 4-[(4-pyridyl)amino]-pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections.

公开(公告)号：US08921355B2

公开(公告)日：2014-12-30

申请号：US13000583

申请日：2009-07-08

Applicant: Sandrine Marie Helene Vendeville ,  Pierre Jean-Marie Bernard Raboisson ,  Tse-I Lin ,  Abdellah Tahri ,  Katie Ingrid Eduard Amssoms

Inventor： Sandrine Marie Helene Vendeville ,  Pierre Jean-Marie Bernard Raboisson ,  Tse-I Lin ,  Abdellah Tahri ,  Katie Ingrid Eduard Amssoms

IPC: A61K31/55 ,  C07D513/12 ,  C07D513/18 ,  C07D515/12 ,  C07D515/18 ,  C07D513/14 ,  A61K45/06 ,  C07D513/22

CPC classification number: A61K31/55 ,  A61K45/06 ,  C07D513/14 ,  C07D513/18 ,  C07D513/22 ,  C07D515/18

Abstract: Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1, R2, R4, R5, R6 and R7 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

Abstract translation: 含有立体化学异构形式的式（I）的HCV复制抑制剂及其盐，水合物，溶剂合物，其中R1，R2，R4，R5，R6和R7具有权利要求中限定的含义。 本发明还涉及制备所述化合物的方法，含有它们的药物组合物及其在HCV治疗中的用途。

公开(公告)号：US08022077B2

公开(公告)日：2011-09-20

申请号：US11914044

申请日：2006-05-12

Applicant: Kenneth Alan Simmen ,  Dominique Louis Nestor Ghislain Surleraux ,  Tse-I Lin ,  Oliver Lenz ,  Pierre Jean-Marie Bernard Raboisson

Inventor： Kenneth Alan Simmen ,  Dominique Louis Nestor Ghislain Surleraux ,  Tse-I Lin ,  Oliver Lenz ,  Pierre Jean-Marie Bernard Raboisson

IPC: C07D471/04 ,  A61K31/519 ,  A61P1/16 ,  A61P31/12

CPC classification number: C07D471/04 ,  A61K31/519

Abstract: The present invention relates to the use of pyrido[2,3-d]pyrimidines of formula (I) wherein L, R1, R2 and R3 have specific meaning. The present invention also relates to the use of the compounds of formula (I) as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds of formula (I) per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.

Abstract translation: 本发明涉及式（I）的吡啶并[2,3-d]嘧啶，其中L，R 1，R 2和R 3具有特定含义。 本发明还涉及式（I）化合物作为HCV复制的抑制剂的用途，以及它们在旨在治疗或对抗HCV感染的药物组合物中的用途。 此外，本发明涉及式（I）化合物本身及其作为药物的用途。 本发明还涉及制备这些化合物的方法，包含它们的药物组合物以及所述化合物与其它抗HCV药剂的组合。

公开(公告)号：US20070155716A1

公开(公告)日：2007-07-05

申请号：US11684288

申请日：2007-03-09

Applicant: Kenneth SIMMEN ,  Tse-I Lin ,  Oliver Lenz ,  Dominique Louis Surleraux ,  Pierre Jean-Marie Raboisson

Inventor： Kenneth SIMMEN ,  Tse-I Lin ,  Oliver Lenz ,  Dominique Louis Surleraux ,  Pierre Jean-Marie Raboisson

IPC: A61K31/55 ,  A61K31/519 ,  A61K31/541 ,  A61K31/5377

CPC classification number: A61K31/517 ,  A61K31/519 ,  A61K31/52 ,  A61K31/53 ,  A61K31/5377 ,  Y02A50/385 ,  Y02A50/387

Abstract: The present invention relates to the use of bi-cyclic pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to processes for preparation of such pharmaceutical compositions. The present invention also concerns combinations of the present bi-cyclic pyrimidines with other anti-HCV agents.

Abstract translation: 本发明涉及双环嘧啶作为HCV复制抑制剂的用途，以及它们在旨在治疗或对抗HCV感染的药物组合物中的用途。 此外，本发明涉及这种药物组合物的制备方法。 本发明还涉及本发明的双环嘧啶与其它抗HCV药物的组合。

公开(公告)号：US20090131460A1

公开(公告)日：2009-05-21

申请号：US11914044

申请日：2006-05-12

Applicant: Kenneth Alan Simmen ,  Dominique Louis Nestor Ghislain Surleraux ,  Tse-I Lin ,  Oliver Lenz ,  Pierre Jean-Marie Bernard Raboisson

Inventor： Kenneth Alan Simmen ,  Dominique Louis Nestor Ghislain Surleraux ,  Tse-I Lin ,  Oliver Lenz ,  Pierre Jean-Marie Bernard Raboisson

IPC: A61K31/519 ,  C07D401/14 ,  A61P31/14

CPC classification number: C07D471/04 ,  A61K31/519

Abstract: The present invention relates to the use of pyrido[2,3-d]pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to pyrido-[2,3-d]pyrimidines compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.

Abstract translation: 本发明涉及吡啶并[2,3-d]嘧啶作为HCV复制的抑制剂的用途，以及它们在旨在治疗或对抗HCV感染的药物组合物中的用途。 此外，本发明涉及吡啶并[2,3-d]嘧啶化合物本身及其作为药物的用途。 本发明还涉及制备这些化合物的方法，包含它们的药物组合物以及所述化合物与其它抗HCV药剂的组合。